Reinthaler M, Braune S, Curio J, Fröhlich G, Jung F and Landmesser U
Trans-catheter pulmonary valve implantation (TPVI) has become the treatment of choice in most congenital heart disease patients with degeneration of a previous right ventricular outflow tract (RVOT) repair. Since the life expectancy of this patient cohort is improving, there is an increased demand of these procedures. Efficacy and safety have been demonstrated for the Medtronic Melody and the Edwards Sapien valves, although there is still a paucity of data and no consistent procedural recommendations are available.